270 related articles for article (PubMed ID: 31794966)
1. Safety and Effectiveness of a 3-Day Rush Insect Venom Immunotherapy Protocol.
Kranert P; Forchhammer S; Volc S; Stenger F; Schaller M; Fischer J
Int Arch Allergy Immunol; 2020; 181(2):111-118. PubMed ID: 31794966
[TBL] [Abstract][Full Text] [Related]
2. Clinical aspects of hymenoptera venom allergy and venom immunotherapy.
Bilò MB; Tontini C; Martini M; Corsi A; Agolini S; Antonicelli L
Eur Ann Allergy Clin Immunol; 2019 Nov; 51(6):244-258. PubMed ID: 31594296
[TBL] [Abstract][Full Text] [Related]
3. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
5. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
6. Venom immunotherapy in patients with allergic reactions to insect stings.
Incorvaia C; Mauro M; Gritti BL; Makri E; Ridolo E
Expert Rev Clin Immunol; 2018 Jan; 14(1):53-59. PubMed ID: 29202591
[TBL] [Abstract][Full Text] [Related]
7. When can immunotherapy for insect sting allergy be stopped?
Müller UR; Ring J
J Allergy Clin Immunol Pract; 2015; 3(3):324-8; quiz 329-30. PubMed ID: 25956311
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
9. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
10. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
11. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis.
Dhami S; Zaman H; Varga EM; Sturm GJ; Muraro A; Akdis CA; Antolín-Amérigo D; Bilò MB; Bokanovic D; Calderon MA; Cichocka-Jarosz E; Oude Elberink JN; Gawlik R; Jakob T; Kosnik M; Lange J; Mingomataj E; Mitsias DI; Mosbech H; Ollert M; Pfaar O; Pitsios C; Pravettoni V; Roberts G; Ruëff F; Sin BA; Asaria M; Netuveli G; Sheikh A
Allergy; 2017 Mar; 72(3):342-365. PubMed ID: 28120424
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
[TBL] [Abstract][Full Text] [Related]
13. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
14. Hymenoptera venom immunotherapy and field stings.
Lang R; Hawranek T
J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom.
Stritzke AI; Eng PA
Clin Exp Allergy; 2013 Aug; 43(8):950-5. PubMed ID: 23889248
[TBL] [Abstract][Full Text] [Related]
16. Natural history and long-term follow-up of Hymenoptera allergy.
Ruëff F
Curr Opin Allergy Clin Immunol; 2020 Oct; 20(5):445-451. PubMed ID: 32739977
[TBL] [Abstract][Full Text] [Related]
17. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
19. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
Gawlik R; Glück J; Jawor B; Rogala B
Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
